Me-too drugs with limited benefits - the tale of regorafenib for HCC

作     者：Gyawali, Bishal Prasad, Vinay 

作者机构：Kings Coll London Inst Canc Policy Guys Hosp Campus London SE1 9RT England Oregon Hlth & Sci Univ Div Hematol Oncol Knight Canc Inst 3181 SW Sam JacksonPk Rd Portland OR 97239 USA Oregon Hlth & Sci Univ Dept Publ Hlth & Prevent Med 3181 SW Sam JacksonPk Rd Portland OR 97239 USA Oregon Hlth & Sci Univ Ctr Hlth Care Eth 3181 SW Sam JacksonPk Rd Portland OR 97239 USA 

出 版 物：《NATURE REVIEWS CLINICAL ONCOLOGY》 

年 卷 期：2017年第14卷第11期

页      面：653-654页

核心收录：

学科分类：1006[医学-中西医结合] 1002[医学-临床医学] 10[医学] 100602[医学-中西医结合临床] 

基　　金：Laura and John Arnold Foundation 

主　　题：Drug Regulations Hepatocellular Cancer approval advance patient treatment Human-centered computing regorafenib 

摘      要：Regorafenib is only the second agent approved by the FDA for the treatment of patients with advanced-stage hepatocellular carcinoma. Herein, we discuss the evidence that led to the approval of this agent. Examination of this process reveals important challenges associated with drug regulation, relating to trial design, treatment toxicity, and real-world clinical *** is only the second agent approved by the FDA for the treatment of patients with advanced-stage hepatocellular carcinoma. Herein, we discuss the evidence that led to the approval of this agent. Examination of this process reveals important challenges associated with drug regulation, relating to trial design, treatment toxicity, and real-world clinical benefit.